Friday, July 11th, 2025

Master card (MA.NYSE):$502.26, break resistance.

“Master card (MA.NYSE):$502.26, break resistance.”
TP1:$510.93
TP2:$520.06
SL:$483.54

Mastercard (NYSE: MA) is a global leader in payment processing technologies. It provides services such as credit, debit, and prepaid card transactions, along with secure payment solutions for businesses and consumers worldwide. Mastercard has consistently maintained its position as a top player in the fintech industry, driven by the rise of digital payments and a shift towards a cashless economy.

As of October 2024, Mastercard’s stock price recently hit $502.26, breaking through a key resistance level, indicating strong market momentum. This follows a series of positive earnings reports. For Q2 2024, Mastercard reported earnings per share (EPS) of $3.59, surpassing analysts’ expectations of $3.51. Its revenue also came in strong at $6.96 billion, beating the forecast of $6.85 billion. This represents an 11% year-over-year revenue growth, reflecting Mastercard’s ability to capture more business globally as digital payments continue to expand.

The company’s next earnings report, expected on October 24, 2024, is anticipated to further reflect strong performance, with EPS estimates at $3.73 and revenue projected at $7.3 billion. Mastercard’s strategic moves, such as partnerships for cross-border payments and innovations in digital payments, continue to solidify its market position. Analysts generally maintain a bullish outlook on the stock, citing its steady growth and robust fundamentals, despite a high price-to-earnings (P/E) ratio of around 30x

Thank you

Eco World Development Surpasses Expectations: Record Sales and Strong Profits Drive Bullish Outlook

Eco World Development: A Detailed Analysis Eco World Development: A Detailed Analysis Date: December 13, 2024 Broker: Maybank Investment Bank Berhad Introduction In the latest research report prepared by Maybank Investment Bank Berhad, the...

CICT Q3 2024 Results: Strong Rental Reversions but Moderation Expected in FY25

Comprehensive Analysis of CapitaLand Integrated Commercial Trust and Peer Comparisons OCBC Investment Research – 5 November 2024 The latest equity research report from OCBC Investment Research provides an in-depth analysis of CapitaLand Integrated Commercial...

Duopharma Biotech (DBB MK) Stock Analysis 2025: Strong Growth Outlook, Higher Target Price & Promising Financials

Broker: UOB Kay Hian Date of Report: 6 June 2025 Duopharma Biotech: Riding the Insulin Wave – Robust Growth, Margin Upside, and Strategic Resilience for 2025 Overview: Duopharma Biotech’s Promising Outlook for Investors Duopharma...